Platelets, cyclooxygenases, and colon cancer

Seminars in Oncology

Volumn 41, Issue 3, 2014, Pages 385-396

  Guillem Llobat, Paloma ^a   Dovizio, Melania ^a   Alberti, Sara ^a   Bruno, Annalisa ^a   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN ENDOPEROXIDE; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR;

ARTICLE; BIOLOGY; CANCER CELL; CLINICAL STUDY; COLON CANCER; COLON CARCINOGENESIS; HUMAN; INFLAMMATION; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION;

ANIMALS; BLOOD PLATELETS; HUMANS; INFLAMMATION; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 84904174276     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.04.008     Document Type: Article

References (94)

1. J.S. You, and P.A. Jones Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22 1 2012 9 20
2. T. Niwa, and T. Ushijima Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis Adv Genet 71 2010 41 56
3. E. Ricciotti, and G.A. FitzGerald Prostaglandins and inflammation Arterioscler Thromb Vasc Biol 31 2011 986 1000
4. D. Wang, and R.N. Dubois Eicosanoids and cancer Nat Rev Cancer 10 2010 181 193
5. G. Davi, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
6. L.J. Gay, and B. Felding-Habermann Contribution of platelets to tumour metastasis Nat Rev Cancer 11 2011 123 134
7. M. Gawaz, H. Langer, and A.E. May Platelets in inflammation and atherogenesis J Clin Invest 115 2005 3378 3384
8. D.L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 2004 387 437
9. M.L. Capone, S. Tacconelli, and L. Di Francesco et al. Pharmacodynamic of cyclooxygenase inhibitors in humans Prostaglandins Other Lipid Mediat 82 2007 85 94
10. K.A. Harper, and A.J. Tyson-Capper Complexity of COX-2 gene regulation Biochem Soc Trans 36 2008 543 545
11. P. Patrignani, S. Tacconelli, A. Bruno, C. Sostres, and A. Lanas Managing the adverse effects of nonsteroidal anti-inflammatory drugs Expert Rev Clin Pharmacol 4 2011 605 621
12. T. Grosser, S. Fries, and G.A. FitzGerald Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J Clin Invest 116 2006 4 15
13. I. Kudo, and M. Murakami Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis J Biochem Mol Biol 38 2005 633 638
14. B. Samuelsson, R. Morgenstern, and P.J. Jakobsson Membrane prostaglandin E synthase-1: a novel therapeutic target Pharmacol Rev 59 2007 207 224
15. Y. Urade, and O. Hayaishi Prostaglandin D synthase: structure and function Vitam Horm 58 2000 89 120
16. S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid receptors: structures, properties, and functions Physiol Rev 79 1999 1193 1226
17. C.L. Bos, D.J. Richel, T. Ritsema, M.P. Peppelenbosch, and H.H. Versteeg Prostanoids and prostanoid receptors in signal transduction Int J Biochem Cell Biol 36 2004 1187 1205
18. K. Nagata, and H. Hirai The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes Prostaglandins Leukot Essent Fatty Acids 69 2003 169 177
19. H. Hirai, K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, and Y. Takamori et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J Exp Med 193 2001 255 261
20. N. Sawyer, E. Cauchon, A. Chateauneuf, R.P. Cruz, D.W. Nicholson, and K.M. Metters et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2 Br J Pharmacol 137 2002 1163 1172
21. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
22. L.A. Garcia Rodriguez, S. Tacconelli, and P. Patrignani Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population J Am Coll Cardiol 52 2008 1628 1636
23. P. Patrignani, M.R. Panara, A. Greco, O. Fusco, C. Natoli, and S. Iacobelli et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J Pharmacol Exp Ther 271 1994 1705 1712
24. C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, and A. De Salvo et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb Res 17 1980 317 327
25. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
26. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anti-cancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 94 2002 252 266
27. D. Wang, and R.N. Dubois The role of COX-2 in intestinal inflammation and colorectal cancer Oncogene 29 2010 781 788
28. L.A. Garcia Rodriguez, L. Cea-Soriano, S. Tacconelli, and P. Patrignani Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials Recent Results Cancer Res 191 2013 67 93
29. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, and G.B. Gordon et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
30. M. Dovizio, S. Tacconelli, E. Ricciotti, A. Bruno, T.J. Maier, and P. Anzellotti et al. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis J Pharmacol Exp Ther 341 2012 242 250
31. D.G. Menter, J.M. Onoda, D. Moilanen, B.F. Sloane, J.D. Taylor, and K.V. Honn Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation J Natl Cancer Inst 78 1987 961 969
32. J.A. Baron, R.S. Sandler, R.S. Bresalier, H. Quan, R. Riddell, and A. Lanas et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 2006 1674 1682
33. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, S.D. Solomon, and K. Kim et al. Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 2006 873 884
34. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, and K. Horgan et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
35. S.M. Prescott Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest 105 2000 1511 1513
36. M. Wang, and G.A. FitzGerald Cardiovascular biology of microsomal prostaglandin E synthase-1 Trends Cardiovasc Med 20 2010 189 195
37. D.A. Dixon, F.F. Blanco, A. Bruno, and P. Patrignani Mechanistic aspects of COX-2 expression in colorectal neoplasia Recent Results Cancer Res 191 2013 7 37
38. P.C. Chulada, M.B. Thompson, J.F. Mahler, C.M. Doyle, B.W. Gaul, and C. Lee et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res 60 2000 4705 4708
39. M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, and E. Kwong et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
40. M. Kulendran, J.F. Stebbing, C.G. Marks, and T.A. Rockall Predictive and prognostic factors in colorectal cancer: a personalized approach Cancers (Basel) 3 2011 1622 1638
41. S.D. Markowitz, and M.M. Bertagnolli Molecular origins of cancer: molecular basis of colorectal cancer N Engl J Med 361 2009 2449 2460
42. H.H. Chang, and E.J. Meuillet Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem 3 2011 1909 1934
43. P.J. Jakobsson, S. Thoren, R. Morgenstern, and B. Samuelsson Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target Proc Natl Acad Sci U S A 96 1999 7220 7225
44. M. Nakanishi, V. Gokhale, E.J. Meuillet, and D.W. Rosenberg mPGES-1 as a target for cancer suppression: a comprehensive invited review 'Phospholipase A2 and lipid mediators' Biochimie 92 2010 660 664
45. M. Nakanishi, D.C. Montrose, P. Clark, P.R. Nambiar, G.S. Belinsky, and K.P. Claffey et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis Cancer Res 68 2008 3251 3259
46. N. Elander, J. Ungerback, H. Olsson, S. Uematsu, S. Akira, and P. Soderkvist Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice Biochem Biophys Res Commun 372 2008 249 253
47. S.C. Pawelzik, N.R. Uda, L. Spahiu, C. Jegerschold, P. Stenberg, and H. Hebert et al. Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1 J Biol Chem 285 2010 29254 29261
48. P. Leclerc, S.C. Pawelzik, H. Idborg, L. Spahiu, C. Larsson, and P. Stenberg et al. Characterization of a new mPGES-1 inhibitor in rat models of inflammation Prostaglandins Other Lipid Mediat 102-103 2013 1 12
49. D.A. Dixon Dysregulated post-transcriptional control of COX-2 gene expression in cancer Curr Pharm Des 10 2004 635 646
50. D.A. Dixon, G.C. Balch, N. Kedersha, P. Anderson, G.A. Zimmerman, and R.D. Beauchamp et al. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1 J Exp Med 198 2003 475 481
51. D.A. Dixon, C.D. Kaplan, T.M. McIntyre, G.A. Zimmerman, and S.M. Prescott Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region J Biol Chem 275 2000 11750 11757
52. C.M. Brennan, and J.A. Steitz HuR and mRNA stability Cell Mol Life Sci 58 2001 266 277
53. J.D. Keene Why is Hu where? Shuttling of early-response-gene messenger RNA subsets Proc Natl Acad Sci U S A 96 1999 5 7
54. L.E. Young, S. Sanduja, K. Bemis-Standoli, E.A. Pena, R.L. Price, and D.A. Dixon The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis Gastroenterology 136 2009 1669 1679
55. D.A. Dixon Regulation of COX-2 expression in human cancers Prog Exp Tumor Res 37 2003 52 71
56. M.R. Fabian, N. Sonenberg, and W. Filipowicz Regulation of mRNA translation and stability by microRNAs Annu Rev Biochem 79 2010 351 379
57. Q. Jing, S. Huang, S. Guth, T. Zarubin, A. Motoyama, and J. Chen et al. Involvement of microRNA in AU-rich element-mediated mRNA instability Cell 120 2005 623 634
58. L.E. Young, A.E. Moore, L. Sokol, N. Meisner-Kober, and D.A. Dixon The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2 Mol Cancer Res 10 2012 167 180
59. A. Strillacci, C. Griffoni, P. Sansone, P. Paterini, G. Piazzi, and G. Lazzarini et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells Exp Cell Res 315 2009 1439 1447
60. M.Z. Michael, SM O'Connor, N.G. van Holst Pellekaan, G.P. Young, and R.J. James Reduced accumulation of specific microRNAs in colorectal neoplasia Mol Cancer Res 1 2003 882 891
61. Y. Akao, Y. Nakagawa, and T. Naoe MicroRNA-143 and -145 in colon cancer DNA Cell Biol 26 2007 311 320
62. X. Chen, X. Guo, H. Zhang, Y. Xiang, J. Chen, and Y. Yin et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis Oncogene 28 2009 1385 1392
63. T. Takagi, A. Iio, Y. Nakagawa, T. Naoe, N. Tanigawa, and Y. Akao Decreased expression of microRNA-143 and -145 in human gastric cancers Oncology 77 2009 12 21
64. M.J. Ochs, D. Steinhilber, and B. Suess MicroRNA involved in inflammation: control of eicosanoid pathway Front Pharmacol 2 2011 39
65. S. Lindemann, N.D. Tolley, D.A. Dixon, T.M. McIntyre, S.M. Prescott, and G.A. Zimmerman et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis J Cell Biol 154 2001 485 490
66. O.P. Barry, M.G. Kazanietz, D. Pratico, and G.A. FitzGerald Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway J Biol Chem 274 1999 7545 7556
67. D.A. Dixon, N.D. Tolley, K. Bemis-Standoli, M.L. Martinez, A.S. Weyrich, and J.D. Morrow et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling J Clin Invest 116 2006 2727 2738
68. S. Eligini, S.S. Barbieri, I. Arenaz, E. Tremoli, and S. Colli Paracrine up-regulation of monocyte cyclooxygenase-2 by platelets: role of transforming growth factor-beta1 Cardiovasc Res 74 2007 270 278
69. B.R. Achyut, D.A. Bader, A.I. Robles, D. Wangsa, C.C. Harris, and T. Ried et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling PLoS Genet 9 2013 e1003251
70. Y. Zhu, M. Zhu, and P. Lance IL1beta-mediated Stromal COX-2 signaling mediates proliferation and invasiveness of colonic epithelial cancer cells Exp Cell Res 318 2012 2520 2530
71. M. Zhu, Y. Zhu, and P. Lance TNFalpha-activated stromal COX-2 signalling promotes proliferative and invasive potential of colon cancer epithelial cells Cell Prolif 46 2013 374 381
72. P.M. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, and T.W. Meade Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
73. P.M. Rothwell, M. Wilson, C.E. Elwin, B. Norrving, A. Algra, and C.P. Warlow et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 2010 1741 1750
74. M. Dovizio, S. Tacconelli, C. Sostres, E. Ricciotti, and P. Patrignani Mechanistic and pharmacological issues of aspirin as an anti-cancer agent Pharmaceuticals (Basel) 5 2012 1346 1371
75. C. Patrono, P. Patrignani, and L.A. Garcia Rodriguez Cyclooxygenase- selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs J Clin Invest 108 2001 7 13
76. C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 6 Suppl 2008 199s 233s
77. P. Patrignani, P. Filabozzi, and C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J Clin Invest 69 1982 1366 1372
78. M. Dovizio, A. Bruno, S. Tacconelli, and P. Patrignani Mode of action of aspirin as a chemopreventive agent Recent Results Cancer Res 191 2013 39 65
79. M.J. Thun, E.J. Jacobs, and C. Patrono The role of aspirin in cancer prevention Nat Rev Clin Oncol 9 2012 259 267
80. J.A. Baron, B.F. Cole, R.S. Sandler, R.W. Haile, D. Ahnen, and R. Bresalier et al. A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891 899
81. R.S. Sandler, S. Halabi, J.A. Baron, S. Budinger, E. Paskett, and R. Keresztes et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 2003 883 890
82. N. Arber, C.J. Eagle, J. Spicak, I. Racz, P. Dite, and J. Hajer et al. Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 2006 885 895
83. X. Jin, Z. Zhu, and Y. Shi Metastasis mechanism and gene/protein expression in gastric cancer with distant organs metastasis Bull Cancer 101 2014 E1 12
84. L.J. Gay, and B. Felding-Habermann Platelets alter tumor cell attributes to propel metastasis: programming in transit Cancer Cell 20 2011 553 554
85. B. De Craene, and G. Berx Regulatory networks defining EMT during cancer initiation and progression Nat Rev Cancer 13 2013 97 110
86. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J Clin Invest 119 2009 1420 1428
87. M. Labelle, S. Begum, and R.O. Hynes Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis Cancer Cell 20 2011 576 590
88. M. Dovizio, T.J. Maier, S. Alberti, L. Di Francesco, E. Marcantoni, and G. Munch et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells Mol Pharmacol 84 2013 25 40
89. M. Ungerer, K. Rosport, A. Bultmann, R. Piechatzek, K. Uhland, and P. Schlieper et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans Circulation 123 2011 1891 1899
90. E.M. Battinelli, B.A. Markens, R.A. Kulenthirarajan, K.R. Machlus, R. Flaumenhaft, and J.E. Italiano Jr Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response Blood 123 2014 101 112
91. A. Mitrugno, D. Williams, S.W. Kerrigan, and N. Moran A novel and essential role for FcgammaRIIa in cancer cell-induced platelet activation Blood 123 2014 249 260
92. A.M. Algra, and P.M. Rothwell Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials Lancet Oncol 13 2012 518 527
93. P.M. Rothwell, M. Wilson, J.F. Price, J.F. Belch, T.W. Meade, and Z. Mehta Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379 2012 1591 1601
94. P.M. Rothwell, J.F. Price, F.G. Fowkes, A. Zanchetti, M.C. Roncaglioni, and G. Tognoni et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 2012 1602 1612